PERSON
Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer
Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial
Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile
Vinay Prasad; FDA; return; Center for Biologics Evaluation and Research (CBER); fewer titles; lower profile; gene therapy; vaccine regulation
Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch
Appia Bio; cell therapy; biotech shutdown; funding challenges; clinical trials; Kite Pharma partnership; oncology; biotech closures; IND application
Funding Drought Puts Pressure on Cell Therapy Startups Like Appia Bio
Appia Bio; cell therapy; funding drought; biotech; venture capital; Series A financing; ACUA platform; CAR-iNKT cells
Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis
Regeneron; Phase 3 trial; cemdisiran; generalized myasthenia gravis; rare disease; RNA drug; siRNA; Alnylam Pharmaceuticals; U.S. regulatory submission
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO
Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership
FDA Rejects PTC’s Vatiquinone Application for Friedreich’s Ataxia, Requests Further Studies
FDA rejection; PTC Therapeutics; vatiquinone; Friedreich’s ataxia; complete response letter; drug efficacy; additional clinical studies
FDA Rejection Derails PTC Therapeutics’ Rare Disease Hopeful
PTC Therapeutics; FDA rejection; vatiquinone; Friedreich’s ataxia; rare disease; efficacy concerns; complete response letter; clinical trial failure
Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements
Kriya Therapeutics; Shankar Ramaswamy; gene therapy; biotech funding; fundraising; biotechnology; venture capital; 2025
Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance
obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials